• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

年龄和吸烟状况影响无癌症个体的血清细胞角蛋白 19 片段水平。

Age and Smoking Status Affect Serum Cytokeratin 19 Fragment Levels in Individuals Without Cancer.

机构信息

Medical Research Institute, Kyoto Industrial Health Association, Kyoto, Japan;

Medical Research Institute, Kyoto Industrial Health Association, Kyoto, Japan.

出版信息

In Vivo. 2022 Sep-Oct;36(5):2297-2302. doi: 10.21873/invivo.12959.

DOI:10.21873/invivo.12959
PMID:36099131
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9463925/
Abstract

BACKGROUND/AIM: Lung cancer is a frequent and fatal cancer that is difficult to diagnose in the early stages. CYFRA 21-1 is a serological marker currently used to diagnose and monitor lung cancer; however, its clinical use for screening is controversial. Therefore, the present study investigated the relationship between serum CYFRA 21-1 levels and clinical confounders.

PATIENTS AND METHODS

We recruited 3,674 individuals who had never been diagnosed with any cancer. The relationships between high serum CYFRA 21-1 levels (≥3.5 ng/ml) and age, sex, body mass index, and smoking status were investigated.

RESULTS

High serum CYFRA 21-1 levels (≥3.5 ng/ml) were detected in 5.1% of all subjects. High serum CYFRA 21-1 levels were observed in 7.3% of current smokers and 4.3% of non-smokers. The proportion of subjects with high serum CYFRA 21-1 levels was markedly higher in the older group (65 years and older, 11%) than in the younger group (younger than 45 years, 2.0%). High serum CYFRA 21-1 levels (≥3.5 ng/ml) were associated with older age [odds ratio (OR)=3.39, 95% confidence interval (CI)=1.79-6.41 for 55-64 years vs. <45 years, and OR=7.34, 95% CI=3.86-13.9 for ≥65 years vs. <45 years, respectively] and current smoking (OR=2.09, 95% CI=1.38-3.15 for current smoker vs. non-smoker).

CONCLUSION

High serum CYFRA 21-1 levels were associated with an older age and current smoking, which may be considered as factors influencing CYFRA 21-1 levels.

摘要

背景/目的:肺癌是一种常见且致命的癌症,早期诊断困难。CYFRA 21-1 是一种目前用于诊断和监测肺癌的血清标志物;然而,其用于筛查的临床应用存在争议。因此,本研究调查了血清 CYFRA 21-1 水平与临床混杂因素之间的关系。

患者和方法

我们招募了 3674 名从未被诊断患有任何癌症的个体。研究了高血清 CYFRA 21-1 水平(≥3.5ng/ml)与年龄、性别、体重指数和吸烟状况之间的关系。

结果

所有受试者中,高血清 CYFRA 21-1 水平(≥3.5ng/ml)的检出率为 5.1%。在当前吸烟者和非吸烟者中,高血清 CYFRA 21-1 水平分别为 7.3%和 4.3%。在年龄较大的组(65 岁及以上,11%)中,高血清 CYFRA 21-1 水平的受试者比例明显高于年龄较小的组(<45 岁,2.0%)。高血清 CYFRA 21-1 水平(≥3.5ng/ml)与年龄较大[年龄 55-64 岁与<45 岁相比,比值比(OR)=3.39,95%置信区间(CI)=1.79-6.41;年龄≥65 岁与<45 岁相比,OR=7.34,95% CI=3.86-13.9]和当前吸烟(当前吸烟者与非吸烟者相比,OR=2.09,95% CI=1.38-3.15)相关。

结论

高血清 CYFRA 21-1 水平与年龄较大和当前吸烟有关,这可能被认为是影响 CYFRA 21-1 水平的因素。

相似文献

1
Age and Smoking Status Affect Serum Cytokeratin 19 Fragment Levels in Individuals Without Cancer.年龄和吸烟状况影响无癌症个体的血清细胞角蛋白 19 片段水平。
In Vivo. 2022 Sep-Oct;36(5):2297-2302. doi: 10.21873/invivo.12959.
2
Variability of serum CYFRA 21 - 1 and its susceptibility to clinical characteristics in individuals without cancer: a 4-year retrospective analysis.血清 CYFRA 21-1 的变异性及其对无癌症个体临床特征的敏感性:一项 4 年回顾性分析。
BMC Pulm Med. 2023 Sep 13;23(1):344. doi: 10.1186/s12890-023-02650-x.
3
[The importance of the tumor marker CYFRA 21-1 in patients with lung cancer after surgery or chemotherapy].[肿瘤标志物CYFRA 21-1在肺癌患者术后或化疗后的重要性]
Hell J Nucl Med. 2007 Jan-Apr;10(1):62-6.
4
Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer.非小细胞肺癌肿瘤组织中细胞角蛋白19表达与血清CYFRA 21-1水平的比较。
Pol Arch Med Wewn. 2009 Jan-Feb;119(1-2):33-7.
5
An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.肿瘤标志物癌胚抗原(CEA)、细胞角蛋白标志物(CYFRA 21-1)和神经元特异性烯醇化酶(NSE)在鉴别孤立性肺良性病变与恶性病变中的评估。
Lung Cancer. 1999 Dec;26(3):149-55. doi: 10.1016/s0169-5002(99)00084-7.
6
Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.细胞角蛋白片段19(CYFRA 21-1)、组织多肽抗原(TPA)和癌胚抗原(CEA)作为支气管癌肿瘤标志物的比较。
Respir Med. 1997 Mar;91(3):135-42. doi: 10.1016/s0954-6111(97)90049-4.
7
Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.血清肿瘤标志物CYFRA 21-1在非小细胞肺癌诊断中的应用
Coll Antropol. 1998 Dec;22(2):629-35.
8
Cytokeratin fragment 19 (CYFRA 21-1) in healthy smokers.健康吸烟者中的细胞角蛋白片段19(CYFRA 21-1)
Anticancer Res. 1999 Sep-Oct;19(5C):4545-6.
9
CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.细胞角蛋白19片段酶联免疫吸附测定。作为非小细胞肺癌肿瘤标志物的评估。
Chest. 1996 Apr;109(4):995-1000. doi: 10.1378/chest.109.4.995.
10
Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.TPS 和 CYFRA 21-1 血清水平升高预示接受吉非替尼治疗的晚期非小细胞肺癌患者预后不良。
Med Oncol. 2010 Sep;27(3):950-7. doi: 10.1007/s12032-009-9315-8. Epub 2009 Oct 15.

引用本文的文献

1
Variability of serum CYFRA 21 - 1 and its susceptibility to clinical characteristics in individuals without cancer: a 4-year retrospective analysis.血清 CYFRA 21-1 的变异性及其对无癌症个体临床特征的敏感性:一项 4 年回顾性分析。
BMC Pulm Med. 2023 Sep 13;23(1):344. doi: 10.1186/s12890-023-02650-x.

本文引用的文献

1
CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort.细胞角蛋白 19 片段 21-1 预测特发性肺纤维化进展:PROFILE 队列的前瞻性纵向分析。
Am J Respir Crit Care Med. 2022 Jun 15;205(12):1440-1448. doi: 10.1164/rccm.202107-1769OC.
2
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.随机试验中 CT 容积筛查降低肺癌死亡率
N Engl J Med. 2020 Feb 6;382(6):503-513. doi: 10.1056/NEJMoa1911793. Epub 2020 Jan 29.
3
Aging and Lung Disease.衰老与肺部疾病
Annu Rev Physiol. 2020 Feb 10;82:433-459. doi: 10.1146/annurev-physiol-021119-034610. Epub 2019 Nov 15.
4
Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy.MILD 试验证实:延长肺癌筛查时间可降低 10 年死亡率,再次确认肺癌筛查的有效性。
Ann Oncol. 2019 Jul 1;30(7):1162-1169. doi: 10.1093/annonc/mdz117.
5
Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.基于循环蛋白生物标志物面板评估肺癌风险。
JAMA Oncol. 2018 Oct 1;4(10):e182078. doi: 10.1001/jamaoncol.2018.2078. Epub 2018 Oct 11.
6
Measurement of Lung Cancer Tumor Markers in a Glass Wool Company Workers Exposed to Respirable Synthetic Vitreous Fiber and Dust.在一家接触可吸入性合成玻璃纤维和粉尘的玻璃棉公司工人中测量肺癌肿瘤标志物
Int J Occup Environ Med. 2018 Jan;9(1):23-31. doi: 10.15171/ijoem.2018.1147.
7
Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units.用于肺癌快速诊断单位指导的高敏标志物检测面板。
Sci Rep. 2017 Jan 24;7:41151. doi: 10.1038/srep41151.
8
Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis.CYFRA 21-1作为非小细胞肺癌预后指标及其与临床病理特征预测相关性的系统评价:一项荟萃分析
Oncotarget. 2017 Jan 17;8(3):4043-4050. doi: 10.18632/oncotarget.14022.
9
Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.肺癌六种血清肿瘤标志物联合检测的评估。
Am J Respir Crit Care Med. 2016 Feb 15;193(4):427-37. doi: 10.1164/rccm.201404-0603OC.
10
Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer.血清细胞角蛋白19片段(Cyfra 21-1)在非小细胞肺癌患者中的预后价值。
Sci Rep. 2015 Apr 22;5:9444. doi: 10.1038/srep09444.